Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Apollo Endosurgery, Inc. stock logo
APEN
Apollo Endosurgery
$9.94
$3.49
$10.30
$579.72M2.311.43 million shs1.66 million shs
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
$0.00
$0.00
$0.00
$0.08
$2K1.024,274 shsN/A
PAVmed Inc. stock logo
PAVM
PAVmed
$0.60
+1.0%
$0.65
$0.55
$1.90
$10.21M1.06136,075 shs19,874 shs
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
$47.71
+5.9%
$44.86
$17.20
$70.26
$155.94M0.1936,079 shs27,791 shs
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
$0.14
+1.8%
$0.15
$0.06
$6.00
$2.95M0.43581,420 shs72,967 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Apollo Endosurgery, Inc. stock logo
APEN
Apollo Endosurgery
0.00%0.00%0.00%0.00%0.00%
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
0.00%0.00%0.00%+200.00%-99.42%
PAVmed Inc. stock logo
PAVM
PAVmed
0.00%-0.50%-5.46%+0.34%-15.68%
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
0.00%+6.31%+12.98%-6.27%+178.52%
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
0.00%-1.20%-9.68%+15.70%-97.23%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Apollo Endosurgery, Inc. stock logo
APEN
Apollo Endosurgery
N/AN/AN/AN/AN/AN/AN/AN/A
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
0.0698 of 5 stars
0.02.00.00.00.00.00.6
PAVmed Inc. stock logo
PAVM
PAVmed
3.9509 of 5 stars
3.55.00.04.30.00.01.9
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
2.4816 of 5 stars
2.52.00.00.02.81.71.9
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
2.421 of 5 stars
3.05.00.00.00.00.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Apollo Endosurgery, Inc. stock logo
APEN
Apollo Endosurgery
0.00
N/AN/AN/A
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
0.00
N/AN/AN/A
PAVmed Inc. stock logo
PAVM
PAVmed
3.00
Buy$19.003,082.58% Upside
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
3.00
Buy$56.0017.38% Upside
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
2.00
Hold$5.003,471.43% Upside

Current Analyst Ratings Breakdown

Latest PAVM, APEN, TTOO, MOTS, and PDEX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/6/2025
PAVmed Inc. stock logo
PAVM
PAVmed
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$19.50 ➝ $19.00
5/27/2025
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$54.00 ➝ $56.00
4/21/2025
PAVmed Inc. stock logo
PAVM
PAVmed
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$19.00 ➝ $19.50
(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Apollo Endosurgery, Inc. stock logo
APEN
Apollo Endosurgery
$76.86M0.00N/AN/A$0.69 per share0.00
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
$319K0.01N/AN/A$1.74 per share0.00
PAVmed Inc. stock logo
PAVM
PAVmed
$1.99M5.12N/AN/A($0.92) per share-0.65
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
$64.12M2.43$0.96 per share49.94$9.03 per share5.28
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
$7.68M0.38N/AN/A($6.91) per share-0.02
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Apollo Endosurgery, Inc. stock logo
APEN
Apollo Endosurgery
-$39.84M-$1.02N/AN/AN/A-51.84%-89.48%-33.76%N/A
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
-$12.87M-$15.64N/AN/AN/AN/AN/AN/A
PAVmed Inc. stock logo
PAVM
PAVmed
$39.79M$0.710.84N/AN/A3,711.54%N/A-42.29%8/12/2025 (Estimated)
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
$2.13M$2.8017.0423.16N/A14.61%29.08%16.19%9/4/2025 (Estimated)
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
-$50.08MN/A0.00N/A-563.16%N/A-174.06%7/28/2025 (Estimated)

Latest PAVM, APEN, TTOO, MOTS, and PDEX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2025Q3 2025
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
$0.47$0.98+$0.51$0.98$17.70 million$17.41 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Apollo Endosurgery, Inc. stock logo
APEN
Apollo Endosurgery
N/AN/AN/AN/AN/A
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
N/AN/AN/AN/AN/A
PAVmed Inc. stock logo
PAVM
PAVmed
N/AN/AN/AN/AN/A
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
N/AN/AN/AN/AN/A
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Apollo Endosurgery, Inc. stock logo
APEN
Apollo Endosurgery
1.04
2.35
1.89
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
N/AN/AN/A
PAVmed Inc. stock logo
PAVM
PAVmed
N/A
0.37
0.37
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
0.28
2.73
1.45
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
N/A
0.40
0.24

Institutional Ownership

CompanyInstitutional Ownership
Apollo Endosurgery, Inc. stock logo
APEN
Apollo Endosurgery
76.01%
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
20.06%
PAVmed Inc. stock logo
PAVM
PAVmed
19.93%
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
15.28%
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
23.18%

Insider Ownership

CompanyInsider Ownership
Apollo Endosurgery, Inc. stock logo
APEN
Apollo Endosurgery
17.30%
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
0.34%
PAVmed Inc. stock logo
PAVM
PAVmed
7.30%
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
47.50%
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
0.03%
CompanyEmployeesShares OutstandingFree FloatOptionable
Apollo Endosurgery, Inc. stock logo
APEN
Apollo Endosurgery
20257.97 million47.94 millionNot Optionable
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
305.77 million5.75 millionNot Optionable
PAVmed Inc. stock logo
PAVM
PAVmed
9017.09 million15.85 millionOptionable
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
1403.26 million1.71 millionNot Optionable
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
18021.04 million21.04 millionOptionable

Recent News About These Companies

TTOO T2 Biosystems, Inc. - Seeking Alpha
T2 Biosystems Inc. (TTOO) After Hours Quote
T2 Biosystems initiates major layoffs, seeks asset sale
T2 Biosystems to be delisted from Nasdaq
T2 Biosystems reports preliminary Q4 revenue $2.3M
T2 Biosystems announces sale of four T2Dx Intruments to European distributor
T2 Biosystems achieves milestone with 250,000th novel sepsis test shipped
T2 Biosystems extends multi-year supplier agreement with Vizient

New MarketBeat Followers Over Time

Media Sentiment Over Time

Apollo Endosurgery stock logo

Apollo Endosurgery NASDAQ:APEN

Apollo Endosurgery, Inc. is a medical technology company, which focuses on the design, development, and commercialization of medical devices to advance gastrointestinal therapeutic endoscopy. It offers Endoscopy, Surgical and Other products. The firm's endoscopy product portfolio consists of the OverStitch Endoscopic Suturing System, the OverStitch Sx Endoscopic Suturing System, and the Orbera Intragastric Balloon System. Its products are used by gastroenterologists and bariatric surgeons in a variety of settings to treat multiple gastrointestinal conditions including closure of acute perforations and chronic fistulas, inadvertent perforation of the GI tract, tissue closure after the removal of abnormal lesions in the esophagus, stomach or colon, the treatment of swallowing disorders, esophageal stent fixation, and obesity. The company was founded by Christopher J. Gostout and Dennis L. McWilliams in 2005 and is headquartered in Austin, TX.

Motus GI stock logo

Motus GI NASDAQ:MOTS

$0.0003 0.00 (0.00%)
As of 07/3/2025

Motus GI Holdings, Inc. operates as a medical technology company in the United States. It develops Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during the colonoscopy and facilitates upper gastrointestinal endoscopy procedures. The company was formerly known as Eight-Ten Merger Corp. and changed its name to Motus GI Holdings, Inc. in November 2016. The company was founded in 2008 and is based in Fort Lauderdale, Florida.

PAVmed stock logo

PAVmed NASDAQ:PAVM

$0.60 +0.01 (+1.02%)
Closing price 07/3/2025 03:54 PM Eastern
Extended Trading
$0.60 0.00 (0.00%)
As of 07/3/2025 04:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.

Pro-Dex stock logo

Pro-Dex NASDAQ:PDEX

$47.71 +2.66 (+5.90%)
As of 07/3/2025 03:49 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Pro-Dex, Inc. designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company's products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California.

T2 Biosystems stock logo

T2 Biosystems NASDAQ:TTOO

$0.14 +0.00 (+1.82%)
As of 07/3/2025 12:05 PM Eastern

T2 Biosystems, Inc., an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood molecular diagnostic test panel that detects lethal form of common blood stream infections, which cause sepsis and candidemia; T2Bacteria panel, a direct-from-blood molecular diagnostic test panel, which detects bacterial pathogens in blood stream infections; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2Biothreat, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument and detects biothreat pathogens. In addition, it is developing T2Cauris panel, a direct-from-blood molecular diagnostic test that runs on the T2Dx Instrument and detects Candida auris; and T2Lyme panel, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument to identify the bacteria that cause Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.